Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line ...

Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received the ...

First-line treatment includes trastuzumab (Herceptin, Genentech) plus chemotherapy. Some patients also receive pembrolizumab (Keytruda, Merck). However, “most patients experience disease ...